This hospital use gives us confidence in the safety and potential of IV glutathione therapy
FDA routinely conducts similar, web-based inspections, which are well suited to reveal a products intended use often the determining factor in whether a product is a drug. See 21 CFR 201.128 (intended use can be derived from a broad array of objective factors, including labeling claims, advertising matter, or oral or written statements.) See also 21 USC 321(g) (defining drug based on, inter alia, its intended use)
GHK-Cu and BPC-157 may contribute to early inflammatory and proliferative phases, while Thymosin beta-4 supports cellular migration and remodeling phases, and KPV provides ongoing anti-inflammatory support throughout the process
Bacteriostatic diluent used in peptide reconstitution suits multi-use vials within 28 days
This might be claimed also for the regimen (the first application 30 min post-transection, the final 24 h before sacrifice) of the given BPC 157 therapy